

References

L-25

1. MammaPrint website. www.agendia.com/healthcare-professionals/breastcancer/mammaprint/.
2. US Food and Drug Administration. FDA clears breast cancer specific molecular prognostic test. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108836.htm.
3. National Comprehensive Cancer Network 2015 Clinical Practice Guidelines in Oncology: Breast Cancer. V.2.2016. www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
4. Harris LN, Ismaila N, McShane, LM, et al. Use of Biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology Clinical Practice Guideline. *J Clin Oncol*. 2016;34(10):1134-50.
5. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. *Annals of Oncology*. 2015;26(5): v8-v30.
6. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies – improving the management of early breast cancer: St. Gallen International expert consensus on the primary therapy of early breast cancer 2015. *Annals of Oncology*. 2015:1-38.
7. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? *Genet Med*. 2009 Jan;11(1):66-73. egappreviews.org/recommendations/breastcancer.htm
8. Sapino A, Ropman P, Linn SC, et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. *J Molecular Diagnostics*. 2014 March;16(2):192-197.
9. Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, et al. Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. *Breast Cancer Res Treat*. 2014;145:697-705.
10. Van de Vijver MJ, He YD, Van'T Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*. 2002 Dec;347(25):1999-2009.
11. Exner R, Bago-Horvath A, Bartsch R, et al. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER- early breast cancer. *Br J Cancer*. 2014;111:837-842.
12. Drukker CA, van Tinteren H, Schmidt MK, et al. Long-term impact of the 70-gene signature on breast cancer outcome. *Breast Cancer Res Treat*. 2014;143:587-592.
13. Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. *Int J Cancer*. 2013;133:929936.
14. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol*. 2007 Dec;8(12):1079-1087.
15. Drukker CA, van den Hout HC, Sonke GS, et al. Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. *Eur J Cancer*. 2014;50:1045-1054.
16. Cusumano PG, Generali D, Ciruelos E, et al. European inter-institutional impact study of MammaPrint. *Breast*. 2014 Aug;23(4):423-8.
17. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. *Eur J Cancer*. 47(18):2742-2749.